KRAS G12C inhibitors and methods of using the same
Brian Alan Lanman, Thousand Oaks, CA (US); Jian Chen, Thousand Oaks, CA (US); Anthony B. Reed, Thousand Oaks, CA (US); Victor J. Cee, Thousand Oaks, CA (US); Longbin Liu, Thousand Oaks, CA (US); David John Kopecky, Thousand Oaks (CA); Patricia Lopez, Thousand Oaks, CA (US); Ryan Paul Wurz, Thousand Oaks, CA (US); Thomas T. Nguyen, Thousand Oaks, CA (US); Shon Booker, Thousand Oaks, CA (US); Nobuko Nishimura, Thousand Oaks, CA (US); Youngsook Shin, Thousand Oaks, CA (US); Nuria A. Tamayo, Thousand Oaks, CA (US); John Gordon Allen, Thousand Oaks, CA (US); and Jennifer Rebecca Allen, Thousand Oaks, CA (US)
Assigned to Amgen Inc., Thousand Oaks, CA (US)
Filed by Amgen Inc., Thousand Oaks, CA (US)
Filed on Sep. 24, 2020, as Appl. No. 17/031,607.
Application 17/031,607 is a continuation of application No. 16/661,907, filed on Oct. 23, 2019, abandoned.
Application 16/661,907 is a continuation of application No. 15/984,855, filed on May 21, 2018, granted, now 10,519,146, issued on Dec. 31, 2019.
Claims priority of provisional application 62/509,629, filed on May 22, 2017.
Prior Publication US 2021/0009577 A1, Jan. 14, 2021